72373-81-0

Basic information

• Product Name: METHYL 2-FLUORO-6-HYDROXYBENZOATE
• Synonyms: RARECHEM AL BF 1190;METHYL 2-FLUORO-6-HYDROXYBENZOATE;METHYL 6-FLUORO-2-HYDROXYBENZOATE;METHYL 6-FLUOROSALICYLATE;2-FLUORO-6-HYDROXY-BENZOIC ACID METHYL ESTER;Methyl 6-fluorosalicylate, 3-Fluoro-2-(methoxycarbonyl)phenol
• CAS NO: 72373-81-0
• Molecular Formula: C₈H₇FO₃
• Molecular Weight: 170.14
• Product Categories: Benzoic acid
• Mol File: 72373-81-0.mol

Chemical Properties

• Melting Point: 71°C
• Boiling Point: 65-70°C 1,7mm
• Flash Point: 96.1 °C
• Appearance: /
• Density: 1.309 g/cm³
• Vapor Pressure: 0.0328mmHg at 25°C
• Refractive Index: 1.526
• Storage Temp.: Inert atmosphere,Room Temperature
• CAS DataBase Reference: METHYL 2-FLUORO-6-HYDROXYBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL 2-FLUORO-6-HYDROXYBENZOATE(72373-81-0)
• EPA Substance Registry System: METHYL 2-FLUORO-6-HYDROXYBENZOATE(72373-81-0)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 72373-81-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
METHYL 2-FLUORO-6-HYDROXYBENZOATE is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drugs with improved therapeutic properties.
Used in Chemical Industry:
In the chemical industry, METHYL 2-FLUORO-6-HYDROXYBENZOATE is utilized as a building block for the creation of various natural products, highlighting its versatility in organic synthesis.
Used in Fragrance and Flavoring Industry:
METHYL 2-FLUORO-6-HYDROXYBENZOATE is used as a component in the production of fragrances and flavorings due to its aromatic properties, adding unique scents and tastes to various products.

InChI:InChI=1/C8H7FO3/c1-12-8(11)7-5(9)3-2-4-6(7)10/h2-4,10H,1H3

Upstream product

• 67-56-1 methanol 
• 67531-86-6 6-fluorosalicylic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 

Downstream Products

• 960249-93-8 methyl 2-[(difluoromethyl)oxy]-6-fluorobenzoate 
• 799262-09-2 5-fluoro-4-hydroxycoumarin 
• 1224594-78-8 C₁₄H₁₇FO₅ 
• 178747-83-6 4-fluoro-benzo[d]isoxazol-3-ol 
• 1331782-39-8 (R)-3-(piperidin-4-ylmethoxy)-4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazole 4-methylbenzenesulfonate 
• 855996-64-4 2-fluoro-N,6-dihydroxybenzamide 
• 108-95-2 phenol 

Relevant articles and documents

WDR5-MYC INHIBITORS

Substituted N-phenyl sulfonamide compounds inhibit WDR5-MYC interactions, and the compounds and their pharmaceutical compositions are useful for treating disorders and conditions in a subject, such as cancer cell proliferation.

Rhodium(III)-Catalyzed Oxidative Intramolecular 1,1-Oxyamination of Alkenes with Protected Amino Acids to Produce Oxazoloisoindole-2,5-diones

It has been established that an electron-deficient bis(ethoxycarbonyl)-substituted cyclopentadienyl (CpE) rhodium(III) complex catalyzes the oxidative intramolecular 1,1-oxyamination of alkenes with N-benzoyl amino acids to produce oxazoloisoindole-2,5-diones. Experimental and theoretical mechanistic studies revealed that this oxidative 1,1-oxyamination proceeds via not the aza-Wacker reaction but the formation of a rhoda(III)oxazolidine initiated by the carboxylic acid-directed N?H bond cleavage.

Discovery and Optimization of Salicylic Acid-Derived Sulfonamide Inhibitors of the WD Repeat-Containing Protein 5-MYC Protein-Protein Interaction

The treatment of tumors driven by overexpression or amplification of MYC oncogenes remains a significant challenge in drug discovery. Here, we present a new strategy toward the inhibition of MYC via the disruption of the protein-protein interaction betwee

MODIFIED COMPOUND OF ANDROGRAPHOLIDE

The present disclosure discloses a modified compound of andrographolide, and particularly discloses a compound shown in formula (I) and (II) or a pharmaceutically acceptable salt thereof.

Two Routes to 4-Fluorobenzisoxazol-3-one in the Synthesis of a 5-HT4 Partial Agonist

A potent 5-HT4 partial agonist, 1 (PF-04995274), targeted for the treatment of Alzheimer's disease and cognitive impairment, has been prepared on a multi-kilogram scale. The initial synthetic route, that proceeded through a 4-substituted 3-hydroxybenzisoxazole core, gave an undesired benzoxazolinone through a Lossen-type rearrangement. Route scouting led to two new robust routes to the desired 4-substituted core. Process development led to the efficient assembly of the API on a pilot plant scale under process-friendly conditions with enhanced throughput. In addition, crystallization of a hemicitrate salt of the API with pharmaceutically beneficial properties was developed to enable progression of clinical studies.

(R)-4-((4-((4-(TETRAHYDROFURAN-3-YLOXY)BENZO[D]ISOXAZOL-3-YLOXY)METHYL)PIPERIDIN-1-YL)METHYL)TETRAHYDRO-2H-PYRAN-4-OL, A PARTIAL AGONIST OF 5-HT4 RECEPTORS

(R)-4-((4-((4-(tetrahydrofuran-3-yloxy)benzo[d]isoxazol-3- yloxy)methyl)piperidin-1-yl)methyl)tetrahydro-2H-pyran-4-ol and its use in treating neurodegenerative disorders, is described herein.

Inhibitors of hepatitis C virus polymerase: Synthesis and characterization of novel 2-oxy-6-fluoro-N-((S)-1-hydroxy-3-phenylpropan-2-yl)-benzamides

SAR exploration from an initial hit, (S)-N-(2-cyclohexenylethyl)-2-fluoro-6-(2-(1-hydroxy-3-phenylpropan-2-ylamino)-2-oxoethoxy)benzamide (1), identified using our proprietary automated ligand identification system (ALIS),1 has led to a novel series of selective hepatitis C virus (HCV) NS5B polymerase inhibitors with improved in vitro potency as exemplified by (S)-2-fluoro-6-(2-(1-hydroxy-3-phenylpropan-2-ylamino)-2-oxoethoxy)-N-isopentyl-N-methylbenzamidecarboxamide (41) (IC50 = 0.5 μM). The crystal structure of an analogue (44) was solved and provided rationalization of the SAR of this series, which binds in a distinct manner in the palm domain of NS5B, consistent with biochemical analysis using enzyme mutant variants. These data warrant further lead optimization efforts on this novel series of non-nucleoside inhibitors targeting the HCV polymerase.

Long-range intrinsic and equilibrium deuterium isotope effects on 19F chemical shifts

Deuterium isotope effects on 19F chemical shifts caused by deuteriation at OH or NH groups have been determined for intramolecularly hydrogen bonded compounds including fluorinated o-hydroxyacyl aromatics, enaminones, o-hydroxyazo and hydrazo compounds. The o-hydroxyazo and hydrazo compounds represent tautomeric and non-tautomeric cases. Deuterium isotope effects on fluorine chemical shifts for o-hydroxyacyl aromatics are found to parallel deuterium isotope effects at the carbon ipso to fluorine. For the azo and hydrazo compounds very long-range effects are seen formally over ten bonds. Throughspace effects are observed in the case of spatially close nuclei like 2-fluorobenzamide-N-α. The isotope effects on 19F chemical shifts can, in p-fluorophenyl substituted cases, be used to monitor the change in equilibrium upon deuteriation and therefore to estimate the importance of hydrogen bonds. Acta Chemica Scandinavica 1997.